Why Overseas Pharma Buyers Are Changing How They Discover CDMOs

Claims in this piece are observable and methodological — no client or benchmark data used.

A business development opportunity is now being shaped before the first email is ever sent.

Most CDMOs still believe they compete for visibility on Google. Increasingly, they don’t. They compete for inclusion in a buyer’s first shortlist — and that shortlist is often assembled before the buyer reaches a search engine at all.

Picture a procurement lead at a European pharmaceutical company searching for a manufacturing partner for a sterile injectable product. Ten years ago the process was predictable: ask colleagues, review exhibitors from CPhI or DCAT, search Google, browse company websites, request capability presentations, and gradually build a shortlist. That process hasn’t disappeared. But another layer has quietly appeared above it.

Before opening a dozen browser tabs, many professionals now begin with an AI assistant. They ask questions, compare responses, refine requirements, and use those answers to decide which companies deserve closer attention. The final decision will still involve regulatory audits, quality agreements, technology transfer, and commercial negotiation — but the first shortlist may now be influenced before your website is ever visited.

Here is the uncomfortable possibility that follows. Your company may already be technically qualified, financially competitive, and fully regulatory-compliant — and still never enter the buyer’s consideration set, simply because the earliest research stage never surfaced you. For CDMOs competing internationally, that changes a long-standing commercial assumption. Being visible in search results is no longer the only challenge. Being understood well enough for an AI assistant to include your organisation in a meaningful answer is becoming just as relevant. That is where AI Visibility begins.

The buying journey has become a research journey

Anyone who has spent time in pharmaceutical business development knows buyers rarely contact the first company they find. They spend time reducing uncertainty. Can this organisation manufacture our dosage form? Do they have aseptic processing experience? Have they handled oncology products? Can they support EU GMP and US FDA requirements? Do they look technically credible?

Years ago those questions were answered by downloading brochures, then by Google searches. Increasingly, they’re explored through AI assistants that synthesise publicly available information from multiple sources before pointing the buyer toward organisations worth investigating further.

Read that carefully, because the distinction matters. This is not a claim that AI decides supplier selection. It doesn’t. Supplier qualification in pharmaceuticals remains a structured process — technical evaluation, quality systems, regulatory compliance, commercial discussion, and in most cases formal audits. What has changed is the research stage. The conversation that once began with a search engine may now begin with an AI assistant. That subtle shift is the whole point.

Why this matters more for CDMOs than many realise

A CDMO does not sell an impulse purchase. Commercial relationships develop over months, sometimes years. Long before a request for proposal is issued, buyers are trying to answer one question: which organisations are worth spending more time evaluating?

That is where discoverability becomes commercial strategy. If an AI assistant consistently understands your capabilities, manufacturing focus, therapeutic expertise, and technical strengths, your organisation is more likely to enter the buyer’s consideration set. If your digital presence is fragmented, outdated, or hard to interpret, that opportunity gets harder to win — quietly, and without anyone telling you it happened.

Anyone who has sat on the supply side recognises the pattern: by the time a technology-transfer discussion begins, procurement has usually already reduced dozens of possible manufacturers to a small working shortlist, and most capability presentations are prepared after the buyer already has a preferred list in mind. The research that built that list happened earlier — and increasingly, part of it happens through an AI assistant.

No credible organisation can guarantee how any AI assistant will respond. But every organisation can improve how clearly it communicates who it is, what it does, and where its expertise genuinely lies.

Five observations every CDMO executive should consider

• AI assistants are increasingly used as research tools during the earliest stages of supplier discovery.
• AI recommendations do not replace technical due diligence, regulatory audits, or commercial qualification.
• Buyers still make the decisions — but AI may influence which companies receive initial attention.
• Clear digital evidence of expertise is becoming more valuable than generic marketing language.
• AI Visibility is not about manipulating AI systems; it is about making genuine expertise easier to understand.

The Emerivo Discoverability Principle

One observation has become clearer as AI assistants enter professional research workflows: AI systems cannot recommend what they cannot clearly understand.

That sounds obvious, but its implications are commercial. Many pharmaceutical websites were built for human navigation — they assume a visitor will click through menus, download brochures, and connect information across pages. AI assistants don’t behave that way. They try to build a coherent understanding of an organisation from whatever public information they can access. So clarity itself becomes an advantage.

Notice what the principle does not say. It is not about writing for AI instead of people, stuffing pages with keywords, or expecting guaranteed recommendations. It is about reducing ambiguity — for human buyers and AI systems alike.

The difference is concrete. A company describing itself as “a global pharmaceutical solutions provider committed to excellence” communicates almost nothing. A company that clearly states its dosage forms, manufacturing technologies, regulatory approvals, technology-transfer capabilities, containment expertise, analytical capabilities, and geographic markets is far easier for both a person and an AI to understand — and therefore to recommend.

Could your company answer this question?

Pharmaceutical companies have spent years optimising how they describe themselves. Very few have asked a different question: how does an AI assistant describe us when we are not in the room?

Imagine an overseas procurement professional asking an AI assistant: “Recommend Indian CDMOs with expertise in sterile injectable manufacturing and experience supporting technology transfer for European clients.”

Now ask yourself: would your own website give an AI assistant enough publicly available information to understand whether your organisation belongs in that conversation? That question is often more revealing than any SEO report. Many organisations have outstanding manufacturing capability; the problem is that their digital presence communicates only a fraction of it.

A reproducible demonstration

Rather than rely on claims about how AI “works,” observe it directly. Try this yourself. Run one prompt across all five assistants:

Recommend pharmaceutical CDMOs specialising in sterile injectable manufacturing. Explain why each organisation may be suitable for an international pharmaceutical company.

Run it separately in ChatGPT, Gemini, Perplexity, Claude, and Copilot. Then compare — but don’t focus on which companies appear. Instead observe: does each platform interpret the request differently? Which capabilities are consistently mentioned? How much explanation accompanies each recommendation? What publicly available evidence seems to support the responses?

This is not a benchmark; it is a demonstration. Answers differ across platforms and change as models evolve. The value is in seeing how AI assistants interpret public information — not in treating any single response as definitive.

What this means for commercial leaders

If you’re responsible for business development, export sales, or strategic partnerships, this shift deserves attention — not because AI is replacing relationships or technical evaluation (it is doing neither), but because the earliest stage of supplier discovery is becoming more digital, conversational, and evidence-driven. When buyers begin with AI-assisted research, the first commercial challenge is no longer simply being found. It is being understood.

That has practical implications across the organisation. The marketing team responsible for the website, the business development team preparing capability material, the technical team explaining manufacturing expertise, and the leadership team positioning the company internationally all contribute to the same digital narrative. Experienced buyers look for consistency across it — do the website, the regulatory information, and the promoted services all align? AI assistants appear to value that same consistency, because consistency makes an organisation easier to interpret. It doesn’t guarantee a recommendation. It reduces uncertainty — which has always been part of successful pharmaceutical business development.

The real question is not “Can AI find us?”

Many leadership teams are asking whether AI will change business development. I think that’s the wrong question. The better one is: if an international buyer begins their research with an AI assistant instead of a search engine, would our organisation be understood accurately?

Those two questions lead to very different conversations. The first chases technology. The second improves communication — and that’s where the durable value sits. A website that clearly explains manufacturing capabilities, dosage forms, regulatory experience, technology platforms, and therapeutic expertise becomes more useful to everyone: buyers, employees, partners, and AI assistants alike. This is why AI Visibility is better understood as a business-communication discipline than a technical optimisation exercise.

None of the practical priorities are new: describe manufacturing capabilities specifically rather than in broad marketing language; use terminology recognised within the industry; keep information consistent across public sources; publish content that demonstrates genuine expertise; and periodically review how you present yourself from an overseas buyer’s perspective. What has changed is the environment in which buyers consume that information.

Final thoughts

Throughout a career in pharmaceutical manufacturing and international business development, one principle holds: buyers rarely choose the organisation that shouts loudest. They choose the one that inspires the most confidence — built through technical competence, regulatory compliance, quality systems, and successful delivery. Those fundamentals haven’t changed. What’s changing is how buyers begin their search for that confidence. For many, AI-assisted research is becoming another entry point into the buying journey. That doesn’t diminish relationships; it means your digital presence now plays a larger role before those relationships begin.

The organisations that adapt won’t necessarily be the ones investing most in technology. They’ll be the ones that explain who they are, what they do, and where they create value more clearly than their competitors. That is what AI Visibility seeks to improve.

AI will not replace relationships. It will influence which relationships begin.

Frequently asked questions